Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy

T. Umapathi, Richard A C Hughes, Eduardo Nobile-Orazio, Jean Marc Léger

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Multifocal motor neuropathy is characterised by progressive, predominantly distal, asymmetrical limb weakness and usually multiple partialmotor nerve conduction blocks. Intravenous immunoglobulin is beneficial but the role of immunosuppressive agents is uncertain. Objectives: To provide the best available evidence from randomised controlled trials on the role of immunosuppressive agents for the treatment of multifocal motor neuropathy. Search strategy: For this update, we searched the Cochrane Neuromuscular Disease Group Trials Register (October 8 2008), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 4), MEDLINE (from January 1966 to October 8 2008), and EMBASE (from January 1980 to October 8 2008), for trials of multifocal motor neuropathy. Selection criteria: Randomised and quasi-randomised controlled trials were to be included and one was found. Prospective and retrospective case series and case reports were considered in the Discussion. Data collection and analysis: Two review authors searched the titles and abstracts of the articles identified and extracted the data independently. Main results: In this update, we found the first randomised controlled trial of multifocal motor neuropathy. This study, which randomised 28 patients, showed that mycophenolate mofetil did not significantly improve strength or function or reduce the need for intravenous immunoglobulin. We summarised the results of retrospective and prospective case series in the discussion. Authors' conclusions: In the only randomised placebo-controlled trial of any immunosuppressive agent, mycophenolate mofetil did not produce significant benefit. Trials of other immunosuppressants should be undertaken.

Original languageEnglish
Article numberCD003217
JournalThe Cochrane database of systematic reviews
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

Immunosuppressive Agents
Randomized Controlled Trials
Mycophenolic Acid
Intravenous Immunoglobulins
Neuromuscular Diseases
Nerve Block
Neural Conduction
Therapeutics
MEDLINE
Patient Selection
Libraries
Extremities
Placebos

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. / Umapathi, T.; Hughes, Richard A C; Nobile-Orazio, Eduardo; Léger, Jean Marc.

In: The Cochrane database of systematic reviews, No. 1, CD003217, 2009.

Research output: Contribution to journalArticle

@article{04ff1db95f3d4bada48f132248b2f71e,
title = "Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy",
abstract = "Background: Multifocal motor neuropathy is characterised by progressive, predominantly distal, asymmetrical limb weakness and usually multiple partialmotor nerve conduction blocks. Intravenous immunoglobulin is beneficial but the role of immunosuppressive agents is uncertain. Objectives: To provide the best available evidence from randomised controlled trials on the role of immunosuppressive agents for the treatment of multifocal motor neuropathy. Search strategy: For this update, we searched the Cochrane Neuromuscular Disease Group Trials Register (October 8 2008), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 4), MEDLINE (from January 1966 to October 8 2008), and EMBASE (from January 1980 to October 8 2008), for trials of multifocal motor neuropathy. Selection criteria: Randomised and quasi-randomised controlled trials were to be included and one was found. Prospective and retrospective case series and case reports were considered in the Discussion. Data collection and analysis: Two review authors searched the titles and abstracts of the articles identified and extracted the data independently. Main results: In this update, we found the first randomised controlled trial of multifocal motor neuropathy. This study, which randomised 28 patients, showed that mycophenolate mofetil did not significantly improve strength or function or reduce the need for intravenous immunoglobulin. We summarised the results of retrospective and prospective case series in the discussion. Authors' conclusions: In the only randomised placebo-controlled trial of any immunosuppressive agent, mycophenolate mofetil did not produce significant benefit. Trials of other immunosuppressants should be undertaken.",
author = "T. Umapathi and Hughes, {Richard A C} and Eduardo Nobile-Orazio and L{\'e}ger, {Jean Marc}",
year = "2009",
doi = "10.1002/14651858.CD003217.pub3",
language = "English",
journal = "Cochrane Database of Systematic Reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy

AU - Umapathi, T.

AU - Hughes, Richard A C

AU - Nobile-Orazio, Eduardo

AU - Léger, Jean Marc

PY - 2009

Y1 - 2009

N2 - Background: Multifocal motor neuropathy is characterised by progressive, predominantly distal, asymmetrical limb weakness and usually multiple partialmotor nerve conduction blocks. Intravenous immunoglobulin is beneficial but the role of immunosuppressive agents is uncertain. Objectives: To provide the best available evidence from randomised controlled trials on the role of immunosuppressive agents for the treatment of multifocal motor neuropathy. Search strategy: For this update, we searched the Cochrane Neuromuscular Disease Group Trials Register (October 8 2008), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 4), MEDLINE (from January 1966 to October 8 2008), and EMBASE (from January 1980 to October 8 2008), for trials of multifocal motor neuropathy. Selection criteria: Randomised and quasi-randomised controlled trials were to be included and one was found. Prospective and retrospective case series and case reports were considered in the Discussion. Data collection and analysis: Two review authors searched the titles and abstracts of the articles identified and extracted the data independently. Main results: In this update, we found the first randomised controlled trial of multifocal motor neuropathy. This study, which randomised 28 patients, showed that mycophenolate mofetil did not significantly improve strength or function or reduce the need for intravenous immunoglobulin. We summarised the results of retrospective and prospective case series in the discussion. Authors' conclusions: In the only randomised placebo-controlled trial of any immunosuppressive agent, mycophenolate mofetil did not produce significant benefit. Trials of other immunosuppressants should be undertaken.

AB - Background: Multifocal motor neuropathy is characterised by progressive, predominantly distal, asymmetrical limb weakness and usually multiple partialmotor nerve conduction blocks. Intravenous immunoglobulin is beneficial but the role of immunosuppressive agents is uncertain. Objectives: To provide the best available evidence from randomised controlled trials on the role of immunosuppressive agents for the treatment of multifocal motor neuropathy. Search strategy: For this update, we searched the Cochrane Neuromuscular Disease Group Trials Register (October 8 2008), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 4), MEDLINE (from January 1966 to October 8 2008), and EMBASE (from January 1980 to October 8 2008), for trials of multifocal motor neuropathy. Selection criteria: Randomised and quasi-randomised controlled trials were to be included and one was found. Prospective and retrospective case series and case reports were considered in the Discussion. Data collection and analysis: Two review authors searched the titles and abstracts of the articles identified and extracted the data independently. Main results: In this update, we found the first randomised controlled trial of multifocal motor neuropathy. This study, which randomised 28 patients, showed that mycophenolate mofetil did not significantly improve strength or function or reduce the need for intravenous immunoglobulin. We summarised the results of retrospective and prospective case series in the discussion. Authors' conclusions: In the only randomised placebo-controlled trial of any immunosuppressive agent, mycophenolate mofetil did not produce significant benefit. Trials of other immunosuppressants should be undertaken.

UR - http://www.scopus.com/inward/record.url?scp=70249128280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249128280&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD003217.pub3

DO - 10.1002/14651858.CD003217.pub3

M3 - Article

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1361-6137

IS - 1

M1 - CD003217

ER -